Ligand Pharmaceuticals Incorporated (LGND)
$120.36 $1.78 (1.50%) 4:38 PM 12/11/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$2.36B -
Day's Range
$118.48 - $121.80 -
Volume
109,287 -
52 Week Low / High
$60.28 - $129.90 -
PE Ratio
50.33x -
PEG Ratio
1.53 -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 3
- Strong Buy
- 4
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong Sell
- $112.67
- Target Price
Company News
-
LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024
By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...
-
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024
Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...
-
LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024
By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...
-
LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024
By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...
-
LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024
By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...
-
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024
Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...
-
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024
Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...
-
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024
Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...
-
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024
Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...
-
Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum? — Sep 25th, 2024
Ligand Pharmaceuticals (NASDAQ:LGND) has had a great run on the share market with its stock up by a significant 28% over the last three months. But the company's key financial indicators appear to be differing across the board and that makes us question whether or not the company's current...
-
LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024
By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...
-
LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024
By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...
-
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024
Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...
-
Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum? — Sep 25th, 2024
Ligand Pharmaceuticals (NASDAQ:LGND) has had a great run on the share market with its stock up by a significant 28% over the last three months. But the company's key financial indicators appear to be differing across the board and that makes us question whether or not the company's current...
-
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024
Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...
-
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024
Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...
-
LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024
By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...
-
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer — Oct 17th, 2024
Palvella Therapeutics Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -...
-
LGND: Initiating Coverage – A Prince Among Royalty — Oct 9th, 2024
By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT We are initiating coverage of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) and assign a valuation of $128 per share. This valuation is based on applying a multiple to our 2025 earnings before interest, taxes, depreci...
Similar Stocks
Portfolio
Comprised of 1 portfolios